China Nuokang Bio-Pharmaceutical, which sells 14 hematological and cardiovascular pharmaceutical products, filed for a US IPO on Friday. The company plans to offer 5 million ADSs, including 473,000 from selling shareholders, at a price between $10 and $12 per ADS. The stock is expected to list on the NASDAQ under the ticker NKBP; Jefferies is the bookrunner on the deal.
